Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: A population-based case-control study

Dorothea C. Torti, Brock C. Christensen, Craig A. Storm, Joan Fortuny, Ann E. Perry, Michael S. Zens, Therese Stukel, Steven K. Spencer, Heather H Nelson, Margaret R. Karagas

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. Objective: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. Methods: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. Results: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. Limitations: Self-reported drug use was a limitation. Conclusions: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.

Original languageEnglish (US)
Pages (from-to)304-312
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume65
Issue number2
DOIs
StatePublished - Aug 1 2011

Fingerprint

Skin Neoplasms
Non-Steroidal Anti-Inflammatory Agents
Case-Control Studies
Anti-Inflammatory Agents
Squamous Cell Carcinoma
Pharmaceutical Preparations
Population
Basal Cell Carcinoma
Aspirin
Odds Ratio
Acetaminophen
Confidence Intervals
Loss of Heterozygosity

Keywords

  • PTCH
  • basal cell carcinoma
  • case-control study
  • nonmelanoma skin cancer
  • nonsteroidal anti-inflammatory drug
  • p53
  • squamous cell carcinoma

Cite this

Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer : A population-based case-control study. / Torti, Dorothea C.; Christensen, Brock C.; Storm, Craig A.; Fortuny, Joan; Perry, Ann E.; Zens, Michael S.; Stukel, Therese; Spencer, Steven K.; Nelson, Heather H; Karagas, Margaret R.

In: Journal of the American Academy of Dermatology, Vol. 65, No. 2, 01.08.2011, p. 304-312.

Research output: Contribution to journalArticle

Torti, Dorothea C. ; Christensen, Brock C. ; Storm, Craig A. ; Fortuny, Joan ; Perry, Ann E. ; Zens, Michael S. ; Stukel, Therese ; Spencer, Steven K. ; Nelson, Heather H ; Karagas, Margaret R. / Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer : A population-based case-control study. In: Journal of the American Academy of Dermatology. 2011 ; Vol. 65, No. 2. pp. 304-312.
@article{d8ddce7f3afb46f79a3a2b23e3bcc8c8,
title = "Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: A population-based case-control study",
abstract = "Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. Objective: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. Methods: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. Results: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95{\%} confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95{\%} confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. Limitations: Self-reported drug use was a limitation. Conclusions: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.",
keywords = "PTCH, basal cell carcinoma, case-control study, nonmelanoma skin cancer, nonsteroidal anti-inflammatory drug, p53, squamous cell carcinoma",
author = "Torti, {Dorothea C.} and Christensen, {Brock C.} and Storm, {Craig A.} and Joan Fortuny and Perry, {Ann E.} and Zens, {Michael S.} and Therese Stukel and Spencer, {Steven K.} and Nelson, {Heather H} and Karagas, {Margaret R.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.jaad.2010.05.042",
language = "English (US)",
volume = "65",
pages = "304--312",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer

T2 - A population-based case-control study

AU - Torti, Dorothea C.

AU - Christensen, Brock C.

AU - Storm, Craig A.

AU - Fortuny, Joan

AU - Perry, Ann E.

AU - Zens, Michael S.

AU - Stukel, Therese

AU - Spencer, Steven K.

AU - Nelson, Heather H

AU - Karagas, Margaret R.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. Objective: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. Methods: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. Results: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. Limitations: Self-reported drug use was a limitation. Conclusions: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.

AB - Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. Objective: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. Methods: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. Results: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. Limitations: Self-reported drug use was a limitation. Conclusions: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.

KW - PTCH

KW - basal cell carcinoma

KW - case-control study

KW - nonmelanoma skin cancer

KW - nonsteroidal anti-inflammatory drug

KW - p53

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79960390257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960390257&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.05.042

DO - 10.1016/j.jaad.2010.05.042

M3 - Article

C2 - 21529996

AN - SCOPUS:79960390257

VL - 65

SP - 304

EP - 312

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -